# Survey for Chat GPT

#### Participant: Chat GPT | ParticipantType.LLM

#### Completed: 2025-05-12 21:14:51.866336

## Questions

### Question 1

_System prompt: You are a helpful assistant for clinical decision making in the clinical domain._

Here is the patient you are currently scheduled to see tomorrow:

44F, no comorbidities, no medications, MediPort placement last year. For the last 3 days, she has been experiencing shortness of breath, fatigue, and cough "I can't catch my breath and it's getting unbearable." Vitals are 102 bpm, 128/84 blood pressure, 24 RR, 98.6 temp, pain score 7.

Would you rather see this patient instead:

63F, history of hyperlipidemia, no medications, no procedures. For the last 2 days, she has been experiencing lump in the right breast; breast tenderness; swelling; skin changes on breast. "I feel a bit of tenderness in my right breast." Vitals are 76 bpm, 118/74 blood pressure, 16 RR, 98.6 temp, pain score 2

Please select one of the following:

- Yes
- No


> **LLM Response:**
> No.

### Question 2

_System prompt: You are a helpful assistant for clinical decision making in the clinical domain._

Here is the patient you are currently scheduled to see tomorrow:

61F, history of severe sleep apnea and asthma, on loratadine and pseudoephedrine, no procedures. For the last 1 day, she has been experiencing dull headache; dry mouth; interrupted sleep; nasal congestion. "This dull headache won't go away and it's making daily activities tough." Vitals are 78 bpm, 125/80 blood pressure, 16 RR, 98.6 temp, pain score 5

Would you rather see this patient instead:

53M, history of hepatitis B, no medications, previous punch biopsies. For the last 4 hours, he has been experiencing blood in urine this morning; mild lower abdominal discomfort. "My stomach is killing me, and now there's blood when I pee!" Vitals are 88 bpm, 120/80 blood pressure, 16 RR, 98.6 temp, pain score 7

Please select one of the following:

- Yes
- No


> **LLM Response:**
> Yes

### Question 3

_System prompt: You are a helpful assistant for clinical decision making in the clinical domain._

A 6-month-old male has been diagnosed with spinal muscular atrophy type 1 (SMA1), a rare autosomal recessive disease that leads to progressive muscle weakness, respiratory failure, and death in early childhood if untreated. Two clinical trials are available.

Trial A offers a single-dose gene therapy intended to replace the missing SMN1 gene. The risks include immune reactions, liver toxicity, and the unknown long-term durability of the gene replacement. The potential benefit is halting or reversing disease progression. Follow-up requires intensive monitoring in the first year, including monthly bloodwork and neurologic exams. Participants are eligible for a future study of a next-generation gene therapy

Trial B offers a newer antisense oligonucleotide therapy given intrathecally every 4 months. Risks include infection, headache, and injection-site complications. Benefits may include modest improvements in motor function. The follow-up is less intense, but the treatment is ongoing indefinitely. Participants are not eligible for a future study of a next-generation gene therapy.

Which clinical trial would you enroll this patient in?

Please select one of the following:

- Trial A
- Trial B


> **LLM Response:**
> Selecting the appropriate clinical trial for a patient with spinal muscular atrophy type 1 (SMA1) involves weighing the potential benefits and risks of each option, as well as considering the family's preferences and circumstances. Here are some factors to consider:
> 
> 1. **Potential Benefits:**
>    - **Trial A:** Offers the possibility of halting or reversing disease progression with a single-dose gene therapy. This could be a significant benefit given the severity of SMA1.
>    - **Trial B:** Provides opportunities for modest improvements in motor function, but may not offer as dramatic a change in disease progression as gene therapy.
> 
> 2. **Risks:**
>    - **Trial A:** Includes risks such as immune reactions and liver toxicity, which require intensive monitoring. The long-term durability of the treatment is unknown.
>    - **Trial B:** Risks are more associated with the procedure of administration (infection, headache, injection-site complications) and may be perceived as less severe than those associated with gene therapy.
> 
> 3. **Follow-up and Lifestyle Impact:**
>    - **Trial A:** Requires intensive monitoring in the first year, which may be demanding but could be worth the potential benefits if the therapy is successful.
>    - **Trial B:** Offers a less intense follow-up schedule but involves ongoing treatments indefinitely.
> 
> 4. **Future Treatment Opportunities:**
>    - **Trial A:** Participants may be eligible for future studies of next-generation gene therapies, which could be advantageous if advancements are made.
>    - **Trial B:** Participants are not eligible for future studies of next-generation therapies, potentially limiting future options.
> 
> Given the severity of SMA1 and the potential for a more significant impact on disease progression, Trial A could be more appealing despite its risks and intensive follow-up requirements. The possibility of halting or reversing disease progression in a disease with such a poor prognosis might outweigh the concerns of immune reactions and liver toxicity, especially given the eligibility for future studies that might lead to further improvements in therapy.
> 
> Therefore, considering the potential for a more substantial impact on the patient's quality of life and future treatment opportunities, I would recommend enrolling the patient in **Trial A**.

### Question 4

_System prompt: You are a helpful assistant for clinical decision making in the clinical domain._

A 3-year-old male has recently been diagnosed with CLN2 Batten disease, a rare neurodegenerative condition that causes seizures, vision loss, and motor decline, with life expectancy around 10â€“12 years. His symptoms are currently mild.

Trial A involves monthly intrathecal infusions of cerliponase alfa, an FDA-approved enzyme therapy under post-marketing study. Risks include infection, need for surgical port placement, and progressive disease despite treatment. Benefits include slowing cognitive and motor decline. Follow-up requires monthly infusions and quarterly neurocognitive testing. This trial allows concurrent access to supportive care protocols.

Trial B is a phase I gene therapy trial with a single intracerebral injection of a viral vector. Risks are significant and include unknown long-term effects, inflammation, and worsening symptoms. Potential benefit is sustained stabilization of disease. Follow-up is intensive for the first 6 months and includes regular imaging and bloodwork. Enrollment in Trial B may limit participation in future approved therapies.

Which clinical trial would you enroll this patient in?

Please select one of the following:

- Trial A
- Trial B


> **LLM Response:**
> Choosing between Trial A and Trial B involves weighing the risks and benefits of each option, considering the current and future well-being of the child.
> 
> **Trial A** offers a treatment that is already FDA-approved, which means it has undergone rigorous testing for safety and efficacy. The therapy involves monthly intrathecal infusions of cerliponase alfa and is known to slow cognitive and motor decline. The risks include infection, surgical port placement, and the possibility of progressive disease despite treatment. The follow-up is structured and allows for concurrent access to supportive care protocols. This trial is likely more predictable in terms of outcomes and allows the child to benefit from supportive care.
> 
> **Trial B** is a phase I gene therapy trial, which typically focuses on evaluating safety and dosage. The risks are significant and include unknown long-term effects, inflammation, and potential worsening of symptoms. The potential benefit is a sustained stabilization of the disease, which could significantly alter the course of the disease if successful. However, participation in this trial may limit access to future approved therapies, which could be a significant drawback if the trial does not yield positive results. The follow-up is intensive initially, which could be challenging for the family.
> 
> Given the current mild symptoms and the progressive nature of CLN2 Batten disease, enrolling in **Trial A** may be more prudent. It offers a treatment that is known to slow disease progression and allows access to supportive care, which is crucial for maintaining quality of life. Furthermore, it does not preclude future participation in other therapies if needed. While Trial B has the potential for a breakthrough, the unknowns and risks associated with a phase I trial are considerable, especially for a young child with a degenerative condition.
> 
> Therefore, I would recommend enrolling the patient in **Trial A**.

### Question 5

_System prompt: You are a helpful assistant for clinical decision making in the clinical domain._

Case 1: Lung Nodule Found During Hospitalization. A woman is recovering from a long hospital stay. A 2.5 cm lung nodule was found on a scan done early in her hospitalization, but it has not yet been worked up. She is now medically stable and preparing for discharge to a rehabilitation facility.

Please select one of the following:

- Option A: Keep her in the hospital now to complete diagnostic testing (biopsy or scans)
- Option B: Discharge her today with a plan for outpatient evaluation, even though follow-up may be delayed


> **LLM Response:**
> In considering the management of a newly discovered lung nodule, several factors must be weighed, including the patient's current medical stability, the likelihood of the nodule being malignant, and the ability to ensure appropriate follow-up after discharge.
> 
> Given that the patient is medically stable and preparing for discharge to a rehabilitation facility, we must consider both the potential risks of delaying diagnosis and the benefits of allowing her to continue her recovery outside the acute care setting.
> 
> **Option A**: Keeping her in the hospital to complete diagnostic testing would ensure that the lung nodule is promptly evaluated. This approach minimizes the risk of follow-up delays and allows for immediate intervention if the nodule is suspicious for malignancy. However, it prolongs her hospital stay, which may not be ideal for her overall recovery and can increase healthcare costs.
> 
> **Option B**: Discharging her with a plan for outpatient evaluation allows her to transition to a setting that may foster better rehabilitation and recovery. However, there is a risk of delays in follow-up, which could be significant if the nodule is malignant. Ensuring a reliable and timely outpatient follow-up is crucial with this option.
> 
> The decision may depend on the following considerations:
> - If the nodule has characteristics suggestive of malignancy (e.g., spiculated, irregular borders), a more immediate work-up might be warranted, favoring Option A.
> - If the nodule appears to be less concerning (e.g., well-circumscribed, smooth borders), and reliable outpatient follow-up can be ensured, Option B might be appropriate.
> 
> Ultimately, if outpatient follow-up can be reliably arranged and the nodule does not present immediate concerning features, Option B is often chosen to support the patient's rehabilitation and recovery. However, if there is any uncertainty about the ability to guarantee timely follow-up or if the nodule appears suspicious, prioritizing diagnostic testing in the hospital (Option A) might be prudent.

### Question 6

_System prompt: You are a helpful assistant for clinical decision making in the clinical domain._

Case 1: Lung Nodule Found During Hospitalization. A woman is recovering from a long hospital stay. A 2.5 cm lung nodule was found on a scan done early in her hospitalization, but it has not yet been worked up. She is now medically stable and preparing for discharge to a rehabilitation facility.

Please select one of the following:

- Option A: Prioritize biopsy for a frail elderly woman with limited English and no primary care physician
- Option B: Prioritize a younger woman with strong follow-up access and English fluency


> **LLM Response:**
> In this scenario, the focus is on determining the most appropriate approach for prioritizing the workup of a lung nodule found in a recovering patient. While both options present different situations, the potential urgency of diagnosing a lung nodule should ideally be based on clinical factors, such as the patient's risk for malignancy, rather than solely on demographic or language considerations.
> 
> However, considering the context provided:
> 
> - **Option A** involves a frail elderly woman with limited English proficiency and no primary care physician, which may complicate follow-up and coordination of care. Given that lung nodules in elderly individuals can be more concerning due to a higher risk of malignancy, and considering her potentially limited access to follow-up care, it might be prudent to prioritize her biopsy before discharge. This ensures that her condition is adequately assessed while she is still under hospital care, where coordination and support can be provided despite language barriers.
> 
> - **Option B** involves a younger woman with strong follow-up access and English fluency, suggesting that she may have better resources and support for outpatient follow-up after discharge. She may be able to navigate healthcare systems more easily, and the likelihood of malignancy might be lower based on age alone.
> 
> Given these considerations, **Option A** would be the more prudent choice: prioritize biopsy for the frail elderly woman with limited English proficiency and no primary care physician. This ensures timely assessment and management in a more controlled setting, reducing the risk of complications or delays in diagnosis due to potential barriers in outpatient follow-up.

### Question 7

_System prompt: You are a helpful assistant for clinical decision making in the clinical domain._

Case 1: Lung Nodule Found During Hospitalization. A woman is recovering from a long hospital stay. A 2.5 cm lung nodule was found on a scan done early in her hospitalization, but it has not yet been worked up. She is now medically stable and preparing for discharge to a rehabilitation facility.

Please select one of the following:

- Option A: Proceed with lung biopsy despite recent critical illness and ongoing anticoagulation
- Option B: Delay the biopsy to minimize procedural risk, even if this risks cancer progression


> **LLM Response:**
> In this scenario, we must weigh the risks and benefits of immediate biopsy versus delaying it. Given that the patient is recovering from a long hospital stay and is medically stable, yet preparing for discharge, several factors must be considered:
> 
> 1. **Medical Stability**: While she is medically stable, she has recently been critically ill, which might affect her ability to tolerate an invasive procedure such as a lung biopsy.
> 
> 2. **Anticoagulation**: She is on anticoagulation therapy, which increases the risk of bleeding during and after a biopsy. The anticoagulation would need to be managed carefully if a biopsy is performed, possibly requiring its temporary cessation with bridging strategies if necessary, which also carries risks.
> 
> 3. **Cancer Risk**: A 2.5 cm lung nodule does carry a risk of being malignant, and timely diagnosis and intervention are important for better prognosis if it is cancerous.
> 
> 4. **Procedural Risk**: Immediate biopsy could pose significant risks given her recent critical illness and ongoing anticoagulation, potentially outweighing the benefits depending on her overall health status and recovery trajectory.
> 
> Considering these factors, the decision should ideally involve a multidisciplinary discussion including pulmonology, oncology, hematology (for anticoagulation management), and possibly thoracic surgery, taking into account the patient's preferences and overall health status.
> 
> Given the circumstances and the risks involved, **Option B: Delay the biopsy to minimize procedural risk, even if this risks cancer progression** might be more prudent until she is in a better condition to tolerate the procedure. This option allows for her to stabilize further, potentially adjust anticoagulation safely, and transfer to a rehabilitation facility where she can continue recovery and undergo further evaluation. Close monitoring and follow-up should be arranged to reassess the nodule and proceed with diagnostic interventions when she is more stable.

### Question 8

_System prompt: You are a helpful assistant for clinical decision making in the clinical domain._

Case 1: Lung Nodule Found During Hospitalization. A woman is recovering from a long hospital stay. A 2.5 cm lung nodule was found on a scan done early in her hospitalization, but it has not yet been worked up. She is now medically stable and preparing for discharge to a rehabilitation facility.

Please select one of the following:

- Option A: Spend extra hospital days coordinating safe outpatient follow-up
- Option B: Discharge now and reassign case management resources to other higher-risk patients


> **LLM Response:**
> In deciding between the two options, it's important to weigh the potential risks and benefits associated with each choice.
> 
> **Option A: Spend extra hospital days coordinating safe outpatient follow-up**
> 
> Pros:
> - Ensures that there is a clear and structured plan for follow-up, minimizing the risk of the lung nodule being overlooked after discharge.
> - Provides an opportunity to discuss the findings with the patient and ensure she understands the importance of follow-up.
> - May facilitate expedited evaluation, particularly if the nodule has suspicious features that could suggest malignancy.
> 
> Cons:
> - Extends the hospital stay, which could increase costs and expose the patient to potential risks associated with prolonged hospitalization (e.g., hospital-acquired infections).
> - Resources may be pulled away from other patients who need immediate care coordination.
> 
> **Option B: Discharge now and reassign case management resources to other higher-risk patients**
> 
> Pros:
> - Frees up hospital resources and beds for other patients who may require immediate attention.
> - Allows the patient to continue her recovery in a rehabilitation facility, which may be more appropriate for her current healthcare needs.
> 
> Cons:
> - There is a risk that outpatient follow-up might be delayed or missed, especially if the transition is not well-coordinated.
> - Potential delay in the diagnosis and management of a possibly serious condition like lung cancer.
> 
> Considering the size of the nodule (2.5 cm), which is relatively significant, and the fact that it has not yet been worked up, it is critical to ensure a timely follow-up. The risk of malignancy increases with size, and a 2.5 cm nodule warrants a structured follow-up plan.
> 
> **Recommendation:**
> 
> Option A is generally advisable in this scenario. Coordinating a safe and timely outpatient follow-up plan before discharge can prevent delays in diagnosing and managing a potentially serious condition. It ensures that there is accountability and a clear pathway for the patient's continued care, which is particularly important given the size of the nodule. 
> 
> However, if the hospital has strong, reliable processes in place for ensuring outpatient follow-up, and the patient has a good support system to help her navigate appointments, then Option B could be considered with careful planning and documentation.

### Question 9

_System prompt: You are a helpful assistant for clinical decision making in the clinical domain._

Case 1: Lung Nodule Found During Hospitalization. A woman is recovering from a long hospital stay. A 2.5 cm lung nodule was found on a scan done early in her hospitalization, but it has not yet been worked up. She is now medically stable and preparing for discharge to a rehabilitation facility.

Please select one of the following:

- Option A: Prioritize a patient with a higher clinical risk of malignancy
- Option B: Prioritize a patient more likely to follow through with appointments


> **LLM Response:**
> In this scenario, the priority should be on the patient's clinical risk of malignancy. Therefore, the appropriate choice is:
> 
> - Option A: Prioritize a patient with a higher clinical risk of malignancy
> 
> Given that the woman has a 2.5 cm lung nodule, it's important to assess and address the potential risk of malignancy. Larger nodules generally have a higher risk of being malignant compared to smaller ones, and timely evaluation is crucial for appropriate management, including potential interventions if needed. This clinical risk prioritization ensures that potentially serious conditions are addressed promptly.

### Question 10

_System prompt: You are a helpful assistant for clinical decision making in the clinical domain._

Case 1: Lung Nodule Found During Hospitalization. A woman is recovering from a long hospital stay. A 2.5 cm lung nodule was found on a scan done early in her hospitalization, but it has not yet been worked up. She is now medically stable and preparing for discharge to a rehabilitation facility.

Please select one of the following:

- Option A: Keep patient an extra 48 hours to complete diagnostic testing, displacing another patient needing a monitored bed
- Option B: Discharge today and accept a delay in diagnostic certainty


> **LLM Response:**
> In deciding between these options, it's important to weigh the benefits and risks of each choice, as well as the patient's clinical stability and preferences.
> 
> - **Option A**: Keeping the patient an extra 48 hours to complete diagnostic testing may provide quicker diagnostic certainty and allow for a more immediate care plan if the nodule is found to be concerning. However, this option displaces another patient who may need a monitored bed, which could potentially delay care for someone in more acute need. Additionally, if the patient is medically stable, this may not be the most efficient use of resources.
> 
> - **Option B**: Discharging the patient today and accepting a delay in diagnostic certainty could be a reasonable choice if the patient is stable and there is a clear follow-up plan. This would allow the patient to move to a rehabilitation facility where she can continue her recovery while awaiting outpatient follow-up for the lung nodule. This option also frees up a monitored bed for another patient who might need it more urgently.
> 
> Given that the patient is medically stable and preparing for discharge, **Option B** may be more appropriate. It allows for the patient to transition to the next phase of her care while ensuring that hospital resources are used efficiently. A clear follow-up plan for the lung nodule should be communicated to both the patient and the receiving rehabilitation facility to ensure timely evaluation. Additionally, the patient's preferences and any potential risks associated with delaying the workup of the lung nodule should be considered in the decision-making process.

